What's new

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised

Feb 9, 2025 - 21:46
 0
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Vabysmo, faricimab, Da...

Next Article

Human medicines European public assessment report (EPAR): Alkindi, hydrocortison...

Related Posts

Cardiovascular Working Party

Cardiovascular Working Party

Feb 9, 2025  0

Questions and answers on implementation of the medical ...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Repaglinide Krka, repaglinide, Date of authorisation: 03/11/2009, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0